Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Chlamydia Market size was valued at USD 3.33 billion in 2024 and is expected to reach USD 9.73 billion by 2037, expanding at around 8.6% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of chlamydia is assessed at USD 3.57 billion.
The growth of the market can be attributed to the increasing prevalence chlamydia and other sexually transmitted diseases, and rise in demand for screening of the disease among people all around the world. According to the World Health Organization, each year, there are an estimated 376 million new infections with 1 of 4 STIs: chlamydia, gonorrhea, syphilis and trichomoniasis. Also, more than 1 million sexually transmitted infections (STIs) are acquired every day worldwide. Along with these, growing number of government initiatives and free diagnostic camps for spreading awareness about sexually transmitted infections is also predicted to be a significant factor driving market growth in the near future. Furthermore, favorable reimbursement policies for companies are evaluated to give impetus to research and development activities associated with the development of novel drugs, which in turn is projected to offer lucrative opportunities for market growth in the forthcoming years.

Chlamydia Sector: Growth Drivers and Challenges
Growth Drivers
- Increasing Prevalence of Sexually Transmitted Diseases Globally
- Rising Demand for Screening of the Disease
Challenges
- Social Stigma Associated with STIs
Chlamydia Segmentation
The market is segmented by test type into culture tests, nucleic acid amplification test (NAAT), direct fluorescent antibody test, serology tests, and others, out of which, the nucleic acid amplification test (NAAT) segment is anticipated to hold the largest share in the global Chlamydia market. This can be accounted to the high accuracy of the test in screening the disease. Apart from these, NAATs allow screening of large number of males and females using self-collected vaginal swabs or using urine without the requirement of a pelvic examination. Additionally, on the basis of route of administration, the oral segment is assessed to acquire the largest share over the forecast period owing to the non-invasive nature, ease of convenience, and cost-effectiveness of this type of route for drug administration.
Our in-depth analysis of the global Chlamydia market includes the following segments:
By Test Type |
|
By Route of Administration |
|
By End User
|
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportChlamydia Industry - Regional Synopsis
Asia Pacific industry is predicted to hold largest revenue share by 2037, on account of growing demand for medical screening and burgeoning need for raising awareness about STIs., on account of growing demand for medical screening and burgeoning need for raising awareness about STIs. In addition, rapid growth of biopharmaceutical industry and rising government support for improving the healthcare infrastructure are also anticipated to drive the region’s market growth in the future. Moreover, the market in North America is projected to grab the largest share during the forecast period ascribing to the high adoption rate of medical screening, high prevalence of STDs, and presence of a large number of pharmaceutical and biopharmaceutical companies in the region. As per the Centers for Disease Control and Prevention, in 2019, a total of 1,808,703 cases of Chlamydia trachomatis infection were reported, making it the most common notifiable condition in the United States for that year.


Companies Dominating the Chlamydia Landscape
- Pfizer, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- GlaxoSmithKline Plc
- AstraZeneca plc
- Gilead Sciences Inc.
- Sanofi Group
- Teva Pharmaceuticals
- Novartis AG
- Abbott Laboratories
- Hologic, Inc.
- Johnson & Johnson Services, Inc.
In the News
-
October 2019- GSK began the phase III clinical program for new chemical class of antibiotic, gepotidacin, in patients with uncomplicated urinary tract infection and STDs.
-
August 2019- Statens Serum Institut, completed the clinical phase 1 trial for first-generation vaccine candidate (CTH522), which is aimed to provide a preventive therapy for chlamydia infection.
Author Credits: Radhika Pawar
- Report ID: 3579
- Published Date: Dec 24, 2024
- Report Format: PDF, PPT